A study in Saudi Arabia found 11.8% of preschool children met Rome IV criteria for functional gastrointestinal disorders, while a Nature study revealed 35.2% of NAFLD patients had IBS, far exceeding global rates.
The Rome IV diagnostic criteria have emerged as a critical tool in identifying functional gastrointestinal disorders (FGIDs) across diverse populations, with recent studies highlighting stark disparities in prevalence and diagnostic gaps. A pilot study in Saudi Arabia revealed that 11.8% of preschool children in Jeddah met Rome IV criteria for FGIDs, while a separate analysis of non-alcoholic fatty liver disease (NAFLD) patients found 35.2% fulfilled IBS criteria, far exceeding global averages.
Saudi Arabia’s FGID Prevalence and Diagnostic Gaps
A Frontiersin study translated the Rome IV Diagnostic Questionnaire into Arabic-Saudi Arabia (Arabic-SA) to assess FGID prevalence among 59 preschool children in Jeddah and its countryside. The research identified 11.8% with functional dyspepsia, 5% with functional constipation, and smaller percentages for other disorders. Researchers emphasized that while this was the first Arabic-SA translation of the questionnaire, its findings—particularly the low prevalence rates—could not be generalized to broader populations due to the study’s small sample size and pilot status.
The study noted that FGID prevalence in Saudi children varies by disorder type, with prior reports indicating 32.2% constipation rates in 2016 and 7.5% diarrhea frequency in children under six. They recommended larger studies to validate these findings, citing the need for a culturally adapted diagnostic tool to address underdiagnosis in the region.
NAFLD Patients Face Disproportionate IBS Burden
A Nature study of 290 NAFLD patients found 35.2% met Rome IV IBS criteria, a rate nearly ten times higher than the global average of 4.3%. This disparity underscores a critical gap in diagnosing IBS among liver disease patients, with 86% of those meeting IBS criteria reporting moderate-to-severe symptoms. The research revealed no gender differences in IBS prevalence among NAFLD patients, contrasting with general population trends where females are 1.5 times more likely to develop IBS.
Notably, IBS symptoms showed no correlation with liver stiffness or fibrosis markers, suggesting independent pathophysiological mechanisms. Researchers highlighted that only 16% of IBS-diagnosed NAFLD patients had prior IBS diagnoses, indicating widespread underrecognition of the condition in liver clinics.
Implications for Clinical Practice and Future Research
Both studies underscore the importance of adopting Rome IV criteria in diverse clinical settings. The Frontiersin researchers advocated for larger, population-based studies to refine FGID prevalence estimates in Saudi Arabia, while the Nature team urged hepatologists to screen NAFLD patients for bowel disorders. They emphasized that early diagnosis could improve symptom management through dietary, medical, and behavioral interventions.
The Nature study also called for standardized IBS severity assessments in NAFLD research, noting that previous literature lacked validated symptom scoring. Researchers warned that undiagnosed IBS in liver clinics may lead to avoidable distress, with 86% of affected patients experiencing severe symptoms. They recommended integrating bowel disorder screening into routine NAFLD care to address this unmet clinical need.
Challenges in Cross-Context Diagnoses
The contrasting populations studied—preschool children in Saudi Arabia versus adult NAFLD patients—highlight the complexity of applying Rome IV criteria across demographics. While the Frontiersin study focused on symptom-based diagnosis in young children, the Nature research examined IBS in patients with comorbid liver disease, revealing no direct link between gastrointestinal symptoms and liver pathology. These findings suggest that FGID mechanisms may vary significantly by age and underlying health conditions.
Both studies also raised concerns about diagnostic underreporting. In Saudi Arabia, the lack of culturally adapted tools may contribute to underdiagnosis, while NAFLD patients often overlook bowel symptoms, delaying treatment. Researchers from both teams called for improved physician training and patient education to bridge these gaps, particularly in regions with limited gastrointestinal specialty care.
